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FIBROBLAST HETEROGENEITY IN PANCREATIC CANCER IMMUNITY

Josephine Kebbeh Darpolor, B.S.

Advisory Professor: Raghu Kalluri M.D, Ph.D

Fibroblasts are a unique cell type defined by their mesenchymal phenotype and exclusion
from epithelial, immune, and endothelial cell subsets. Although well studied in wound
healing, cancer associated fibroblasts (CAFs) are incredibly heterogeneous, leading to
contradictions as to the roles CAFs play in the tumor microenvironment (TME). CAFs were
thought to be a barrier to treatment of pancreatic ductal adenocarcinoma (PDAC). However,
general stromal targeting strategies have largely failed in the clinic likely due to the
heterogeneity of CAFs in the TME. Therefore, our groups and others have worked to
unravel the heterogeneity of CAFs in PDAC. In the works presented herein, we seek to
identify the functions of two commonly studied CAF subsets defined by expression of aSMA
and FAP.

We employed single cell RNA sequencing, mass cytometry, and multiplex
immunohistochemistry to assess genetically engineered mouse models (GEMMs) in which
we could deplete aSMA+ and FAP+ CAFs. We found the aSMA+ and FAP+ CAFs were
distinct subsets with tumor restraining and tumor supporting roles, respectively. aSMA+
CAFs were immune stimulatory and associated with prolonged survival in GEMMs.
Meanwhile, FAP+ CAFs were immunosuppressive and correlated with shortened survival in
GEMMs. Altogether, we discovered that aSMA+ and FAP+ CAFs are distinct CAF
populations with opposing roles in PDAC progression and immunity.
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Chapter 1

Background and Significance

1

Fibroblasts in the wound
Tissue repair is a crucial aspect of animal survival typically defined by 4 stages1. After injury
to an organ the tissue will begin a series of processes including hemostasis, inflammation,
proliferation, and remodeling and maturation. Clotting factors that lead to the coagulation of
blood are released during hemostasis. During the stage of inflammation, immune cells are
activated resulting in the destruction and phagocytosis of pathogens and release of
cytokines and chemokines. Toward the end of the inflammatory phase, cytokines are
released that activate fibroblasts1–3. Fibroblasts are a non-immune, non-epithelial, nonendothelial, mesenchymal cell type commonly known for the role they play in synthesizing
and remodeling of extracellular matrix (ECM) within the stroma and connective tissue.
During the proliferation stage, fibroblasts secrete collagen and remodel the ECM to rebuild
the tissue while simultaneously closing the wound. In the final stage of wound healing the
fibroblasts continue to remodel the ECM after the blood vessels reform and the epithelial
cells resurface. The remodeling and maturation stage can last from months to years. Each
phase of wound healing is tightly regulated. However, in cases of aberrant wound healing
responses where phases are not properly resolved such as in uncontrolled inflammation or
proliferation, serious pathologies may occur4. Excessive inflammation and cellular
proliferation contribute to the premalignant- niche associated with cancer development. The
connection between tissue repair and cancer has led to cancer becoming commonly known
as the wound that never heals. In cancer, fibroblasts undergo epigenetic changes that
results in chronic activation and aberrant wound healing-like responses that support
pathogenesis in the tumor microenvironment (TME)3,5,6.

Origins of CAFs
Although the functions of fibroblasts in wound healing have been extensively studied, the
origins of fibroblasts remain unknown and the heterogeneous functions of cancer associated
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fibroblasts (CAFs) are poorly defined. Studies suggest several possible origins of fibroblasts
including tissue resident fibroblasts, adipocyte stem cells, endothelial cells, epithelial cells,
hematopoietic stem cells (HSCs), and mesenchymal stem cells (MSCs)7. Resident
fibroblasts are thought to be the main contributor to the CAF population8. As inflammation
occurs during cancer development, growth factors, cytokines, and metabolites are secreted
by epithelial, endothelial, and immune cells that lead to the activation of stellate cells. When
fibroblasts become activated in the TME they upregulate their expression of common CAF
markers including asmooth muscle actin (aSMA), platelet derived growth factor receptor a
(PDGFRa), platelet derived growth factor receptor b (PDGFRb), vimentin, fibroblast
activating protein (FAP), and fibroblast specific protein 1 (FSP1)7,9–12. Adipocyte stem cells
can be of bone marrow or tissue origin and when stimulated by cancer cells differentiate into
aSMA+ fibroblasts, also known as myofibroblasts13. Endothelial to mesenchymal transition
(EndMT) has been well documented by our lab and others as a contributor to CAFs14–17.
EndMT occurs when endothelial cells differentiate into mesenchymal cells as they lose
CD31 expression and begin to express common fibroblast markers such as aSMA14–16,18,19.
Similar to EndMT, epithelial to mesenchymal transition (EMT) has been shown to be a
contributor to the CAF population20–24. EMT is the most extensively studied mesenchymal
transition. A discovery made by developmental biologists, EMT was first known to be pivotal
in embryogenesis and organ development20,22,24. As epithelial stem cells proliferate and
differentiate to form new tissues they can take on a mesenchymal phenotype that enables
them to detach from the basement membrane and become more migratory, downregulate
apoptotic programing, invade the surrounding tissue, and produce extracellular matrix25,26. A
reversible process, cells that undergo EMT can then revert back to an epithelial phenotype
through mesenchymal to epithelial transition (MET). EMT is used in embryogenesis to
develop cells with unique functions within the organ. Generally, epithelial cells perform
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organ functions and mesenchymal cells develop the tissue structure and assist in epithelium
functions. As is common with many embryonic processes, EMT is turned on in cancer22.
EMT is hijacked during tumorigenesis and is associated with therapeutic resistance, cancer
recurrence, and metastasis17,20,21,23,27. For decades, in the field of oncology, EMT was
thought to be necessary for metastasis development. However, in recent years it was shown
that even without EMT, metastasis can still occur28. The change in functions associated with
EMT are accompanied by a switch in expression of epithelial markers to mesenchymal
markers. The co-expression of epithelial and mesenchymal markers can be used as a way
to recognize cells in the process of EMT or MET. Resident cells of mesenchymal, adipocyte,
endothelial, and epithelial origin are extensively studied as the main origins of CAFs, but as
the field began assessing the specific contributions of different cell types to the TME, it was
quickly recognized that resident cells are not the only contributors to CAFs. In fact, it is now
very well accepted in TME research that there are bone marrow origins of CAFs.
Both major stem cell populations within the bone marrow, HSCs and MSCs are
documented to migrate to the TME and give rise to CAFs29–34. In studies using GFP mice to
perform bone marrow transplantations a group found that HSCs can migrate to the TME and
differentiate into fibroblasts. HSCs gain CD45 expression as part of their differentiation into
more mature immune cell populations29,30,35. However, when immune cells transition to
become CAFs, they lose CD45 expression and begin to express type 1 collagen and
aSMA29,30. Although there are few studies addressing the HSC origin of CAFs in cancer,
fibroblasts expressing immune markers, also known as fibrocytes, are known to exist in
infection, fibrosis, and cancer36–40. However, whether there is a unique function of these
particular fibroblasts or if they aberrantly express immune markers in disease context is not
currently known. HSCs share the bone marrow niche with another important stem cell
population, MSCs. MSCs are the stem cells that give rise to all major mesenchymal cell
types including, osteoblasts, chondrocytes, myocytes, and adipocytes41. Historically
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fibroblasts were also thought to derive solely from MSCs. However, it’s now believed that
fibroblasts may arise from multiple stem cell populations during development. Using
common markers and bone marrow transplantation studies, groups have shown the ability
for MSCs to thrive in the TME, contribute to tumor progression, differentiate into CAFs, and
activate resident cells to become CAFs16,31–34,41,42. Even with new tools such as in vivo
lineage tracing in murine models and intravital imaging, the complete origins of CAFs
continue to elude the field. However, several studies have explored the functions of
fibroblasts from diverse origins by comparing bone marrow derived CAFs with resident
tissue derived CAFs with many suggesting that the origins of fibroblasts can influence their
functions as well as the residential organ milieu in which they migrate to33. The origins and
functions of CAFs have been studied in colorectal and breast cancer, but with the lack of
therapeutic options, dismal survival rates and characteristic desmoplastic reaction,
pancreatic ductal adenocarcinoma (PDAC) presents the most enticing model to study CAF
origins and functions.

Stroma as a barrier to therapy in PDAC
Desmoplasia can be seen throughout the progression of PDAC. The development of PDAC
has been divided into unique stages. The precancerous lesions associated with PDAC
development are called pancreatic intraepithelial neoplasms or PanIN43–45. It is when these
lesions have broken through the basement membrane that they become malignant PDAC.
Although fibroblasts are invaluable to the process of wound healing, in cancer the functions
of fibroblasts are dichotomous. CAFs are a common cellular component in the stroma
associated with the desmoplasia in PDAC. PDAC is one of the leading causes of cancer
death in the United States with a five-year survival rate of 7%. Early studies suggested that
the stroma contributes to the therapeutic recalcitrance of PDAC by protecting cancer cells
with physical barriers and metabolic support9,46–48. Therefore, the field began employing
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general stromal targeting strategies in hopes of disrupting the desmoplasia and augmenting
standard of care treatments such as chemotherapy and radiation47–49. However, these
general stromal targeting strategies have largely failed, with some clinical trials resulting in
detrimental effects in patient survival. In response to the unsuccessful clinical trials, groups
began studying the functions of CAFs in PDAC more extensively. It was discovered that a
subset of CAFs are tumor suppressing which may account for the poor results of general
stromal targeting strategies. Several studies assessing the role of CAFs in PDAC have
shown heterogeneous functions, including tumor suppressing, tumor promoting, ECM
remodeling and immune modulating9–12,50,51. CAFs expressing FAP and aSMA have been
particularly well studied in PDAC50,52–56.

Heterogeneous CAF Functions
As the TME field continues to decipher the many heterogeneous roles of CAFs, several
markers have become commonly used to define subsets of CAFs. However, no marker has
yet to encompass the entire CAF population, and no marker is exclusively expressed within
the CAF population. Complications with identifying true CAFs has made studying them
difficult. Yet by using markers EpCAM, CD45, and CD31 to exclude epithelial, immune, and
endothelial cells, respectively, we can then assess CAFs by the expression of common
mesenchymal markers. Studies have used reporter mice, lineage tracing, and single cell
RNA sequencing (scRNAseq) to understand the heterogeneity of CAFs, establishing that
unique CAF subsets exist in PDAC with varying functions in the TME. Of particular interest,
certain subsets of CAFs have been suggested to have immune modulating capacities.
While immunotherapy has shown great promise in many cancers, there has been very little
success in PDAC. The CAF-immune crosstalk documented in cancer is one area of
research that has the potential to illuminate strategies to augment immunotherapy in
cancer57–60. Mechanisms of immune suppression by CAFs has been well documented, but
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studies suggesting a role of immune stimulating CAFs in PDAC confound the field. Groups
employing genetically engineered mouse models (GEMMs) demonstrate that when specific
subsets of fibroblasts are depleted from the TME in conjunction with immune checkpoint
blockade administration, tumor regression occurs. When the CXCL/CXCR2 axis between
fibroblasts and cancer cells is blocked there is decrease in the presence of
immunosuppressive immune subsets, specifically neutrophils, myeloid derived suppressor
cells (MDSC), and M2 tumor associate macrophages (TAMs)57,58. Similarly, in a study
blocking the CXCR4/CXCL12 axis authors found that they were able to augment immune
checkpoint blockade in a T-cell specific manner57,61. Additionally, our group and others found
that when aSMA+ CAFs are depleted from the tumor microenvironment, it results in
immunosuppression in the TME as represented by the shift in the CD8+/CD4+Foxp3+ ratio
with an increase in aCTLA4 checkpoint immunotherapy efficacy50,54. The fibroblast-immune
crosstalk in PDAC may present an opportunity for new immunotherapeutic regimens.

Immunotherapy in PDAC
Immunotherapy has shown great promise in cancer. Vaccines, checkpoint inhibitors, tumor
infiltrating lymphocyte (TIL) therapy, T-cell receptor (TCR) therapy, and chimeric antigen
receptor T-cell (CAR-T) therapies are common treatments utilized in oncology. While many
immunotherapies have found great success in blood cancers and highly immunogenic
cancers, there has been far fewer successes in cold, solid tumor types, including PDAC62–64.
Many trials have failed, offering no survival benefit or resulting in adverse effects so severe
that trials were halted.
Vaccines
Cancer vaccines are vaccines used to produce adaptive immune cells specific
against certain tumor types. These vaccines can be cell, peptide or genetic based. However,
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regardless of the contents of the vaccine, the principles remain the same. Many vaccinebased immunotherapies have been tested in clinical trials in combination with chemotherapy
and as single agents61,63,65–67. GV1001 is a telomerase vaccine that entered phase III of
clinical trials but failed to show efficacy. Despite the questionable effectiveness of GV1001
as an immunotherapy for pancreatic cancer, it was approved in Korea highlighting the
desperate need for new therapies in PDAC68. Several peptide vaccines have made it
through phase I or II of clinical trials and showed similar dismal results.
Checkpoint Blockade
One form of immunotherapy that has recently led to the awarding of two Nobel
Prizes is immune checkpoint blockade. When T-cells are activated they upregulate their
expression of PD-1 and CTLA469. When these checkpoints are engaged it dampens the
immune response. Therefore, groups used antibodies against CTLA4, PD1, and PDL1 to
block these breaks from being engaged in the TME with promising results. Unfortunately,
checkpoint blockade has shown little efficacy in PDAC with partial tumor regression and
limited survival benefit61,69,70.
TIL Therapy
As opposed to stimulating the immune system with proteins, peptides, or genetic
components, in TIL therapy, T-cells are isolated directly from the patient’s tumor and
expanded ex vivo71,72. The idea is that this method will result in increasing the number of Tcells with receptors against the cancer cells. In some cases, T-cells are preferentially
selected for CD8 positivity and other important markers. The cells are then infused back into
the patient. TIL therapy has the advantage that the T-cells have previously been exposed to
the TME and can therefore home back to the tumor site upon infusion. The preclinical
models for TIL therapy in PDAC are promising, but the clinical trials will likely see many of
the same roadblocks as previous immunotherapies unless combined with other therapies.
TCR Therapy
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Unlike TIL therapy, TCR therapy typically uses autologous T-cells isolated from
peripheral blood mononuclear cells (PBMCs) obtained through leukapheresis. T-cells are
then activated and transduced or transfected to express a specific T-cell receptor. This
method is more expensive than TIL therapy, but has the added benefit of control of TCR
specificity that doesn’t exist with TIL therapy. However, one of the main downfalls of this
immunotherapy in addition to the cost, is that each TCR will be limited to the patients who
can use it due to the HLA types patients express.
CAR-T
Similar to TCR therapy, autologous T-cells are harvested from patients to produce
CAR-T. However, as opposed to transducing the T-cells to express specific T-cell receptors,
these cells are transduced to express a specific antibody against tumor antigens. This offers
the advantage that use of an antibody obviates the limitations seen with TCR therapy as the
HLA type of the patient would not affect the ability of the patient to receive the treatment.
Although price of production, T-cell anergy upon infusion, and adverse events in clinical
trials has diminished the enthusiasm for CAR-T therapy in recent years, there are still new
CAR-T being created in hopes of discovering viable strategies for solid tumors, including
PDAC. One CAR-T that has been used in solid tumors targets carcinoma embryonic antigen
(aCEA CAR-T).
Two major issues with immunotherapies are resistance and adverse events73,74. The
immunosuppressive microenvironment makes it hard to stimulate anti-tumor immunity and
can result in the anergy of even T-cells that have been activated and infused into the
patient. Furthermore, the immune stimulation from immunotherapies often results with
unintended and off-target affects. To augment off target affects, groups have tried different
infusion methods. Traditionally, these therapies are infused intravenously. However, some
groups have performed intratumoral and hepatic artery infusions to abrogate off-target
effects.
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There are several other immunotherapies in trials or approved for other cancers.
However, the current outlook for single agent immunotherapy success in PDAC is bleak.
Although immunotherapy has not had great success in PDAC, as we begin to learn more
about the TME and the cells within, combinations of immunotherapies or immunotherapy
and other forms of treatment may prove affective. Many combination therapies are currently
being tested. As the field deconvolutes the CAF populations in PDAC, combining strategies
that specifically target pro-tumorigenic CAFs with immunotherapies, may result in a less
immunosuppressive microenvironment; which would allow efficient targeting of cancer cells
and augment therapeutic efforts in PDAC.

Dissertation goals and major findings
The heterogeneity of CAFs has been well documented. It is currently known that CAFs have
several functions within the TME including: ECM remodeling, tumor promoting, tumor
suppressing, aiding metastasis, regulating the tumor immune microenvironment, metabolic
reprogramming, and likely many others that have yet to be uncovered. Although studies are
now recognizing that there may be unique subsets of fibroblasts that have specific roles in
the TME, these subsets have yet to be thoroughly defined. The aim of this work was to
elucidate fibroblast populations using common mesenchymal markers that were either tumor
promoting or tumor restraining in order to target specific populations and augment
therapeutic efforts in pancreatic cancer.
In an effort to conduct a comprehensive study on the functions of distinct CAF
populations, we employed single cell RNA sequencing (scRNAesq) and Mass Cytometry
(CyTOF) to assess the heterogeneity of CAFs in PDAC that our lab and many other groups
had previously described. CAFs in PDAC express a diverse repertoire of mesenchymal
markers with high representation of fibroblasts expressing vimentin, PDGFRa, FSP1 and
aSMA. In our models FAP and PDGFRb expressing CAFs were less represented. We next
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showed that there were vast differences in the stromal makeup when you compare tumors
at different stages. However, throughout progressive stages of murine PDAC we found that
aSMA+ and FAP+ CAFs were exclusive subsets and most abundant in late tumor stages
when the mice were at survival end point. We confirmed the minimal overlap of aSMA+ and
FAP+ CAF populations in human tissues, suggesting that our findings are relevant to human
disease.
After discovering that aSMA+ and FAP+ CAFs were distinct in PDAC, we sought to
address the question of whether they also performed unique functions in the TME. We
utilized pancreatic cancer GEMMs in which we could target specific fibroblast subsets to
assess the functions of CAFs in the TME. Depletion of aSMA+ and FAP+ CAFs resulted in
tumor progression and tumor suppression, respectively, as defined by changes in histology
and murine survival. In order to assess the mechanisms by which FAP and aSMA
expressing CAFs influence the TME we performed microarray analysis on whole tumors
depleted of either aSMA+ or FAP+ CAFs. Transcriptomic analysis revealed that when aSMA+
or FAP+ CAFs are depleted from the TME unique genetic pathways are downregulated and
upregulated. FAP+ CAFs were associated primarily with pathways involved in immune
regulation and aSMA+ CAFs were associated with pathways related to EMT, collagen
deposition, and ECM remodeling. In response to our finding that FAP expressing CAFs were
immune modulatory, we carried out immunohistochemistry multiplexing to assess the
changes in the immune landscape when aSMA+ or FAP+ are depleted from the TME. We
confirmed our previous finding that when aSMA+ CAFs are depleted the effector T-cell
(Teff)/ regulatory T-cell (Treg) ratio decreases and presence of myeloid cells increases,
leading to immune suppression, and found that depletion of FAP expressing CAFs from the
TME results in a decrease in myeloid cells in the TME.
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Altogether, we discovered two distinct subsets of CAFs with opposing roles in PDAC
progression and unique functions in tumor immunity.
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Chapter 2

Materials and Methods
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Mice
All acronyms designating specific genetically engineered mice (GEM) are listed below:
Nomenclature

Definition

Reference

KPC

Pdx1cre/+;LSL-KrasG12D/+;Trp53R172H/+

(Hingorani et al.,
2003)75

KPCY

KTC

Pdx1cre/+;LSL-KrasG12D/+;Trp53R172H/+;Rosa26-

(Hingorani et al.,

LSL-YFP

2003)75

Ptf1acre/+;LSL-KrasG12D/+;Tgfbr2loxP/loxP

(Moses et al., 2006;
LeBleu et al., 2013;
Ozdemir et al.,
2015) 50,76,77

KTCY; aSMA-

Ptf1acre/+;LSL-KrasG12D/+;Tgfbr2loxP/loxP;Rosa26-

(LeBleu et al., 2013;

RFP

LSL-YFP; aSMA-RFP

Ozdemir et al.,
2015) 50,77

KTC; aSMA-TK

KTC;FAP-TK

FAP-TK

Ptf1acre/+;LSL-KrasG12D/+;Tgfbr2loxP/loxP; aSMA-TK

(LeBleu et al., 2013;

(enables depletion of proliferating aSMA+ cells

Ozdemir et al.,

with GCV)

2015) 50,77

Ptf1acre/+;LSL-KrasG12D/+;Tgfbr2loxP/loxP;FAP-TK

(Ozdemir et al.,

(enables depletion of proliferating FAP+ cells

2015), Kalluri

with GCV)

laboratory

Transgenic strain that enables depletion of

Kalluri laboratory

proliferating FAP+ cells with GCV

The FAP-TK transgenic strain was newly generated. A 5 kb sequence flanking the FAP
promoter and partial Exon 1 (Ex1) was cloned into pORF-HSV1-TK vector (Invivogen) using
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Not I and Age I. The sequence-confirmed FAP-TK construct was released from the vector
using Not I and Swa I before purification and injection into fertilized eggs. The transgenic mice
were generated in the MD Anderson Genetically Engineered Mouse Facility on the C57Bl/6
genetic background. These mice were bred onto PDAC GEM or implanted orthotopically with
689KPC cancer cells, as previously described. Mice were maintained on a mixed genetic
background and both male and female mice were evaluated. Ganciclovir (GCV; sud-gcv,
Invivogen) was administered i.p. daily at 50 mg/kg of body weight (approximating 1.5 mg per
25g mouse). GCV was administered to KTC mice at 21 to 37 days of age. Control groups
were TK negative mice that received GCV, phosphate buffer saline (PBS), or were not
injected. In the orthotopic tumor model (689KPC), GCV was administered 15 days following
tumor implantation and mice were euthanized at 40 days following tumor implantation78. All
mice were housed under standard housing conditions at MD Anderson Cancer Center
(MDACC) animal facility, and all animal procedures were approved by the MDACC
Institutional Animal Care and Use Committee. Investigators were not blinded to group
allocation but were blinded for the histological assessment of phenotypic outcome with no
randomization method used. The experimental endpoint was defined when the animals
developed significant signs of illness leading to their death or requiring euthanasia. Survival
curves for KTC mice are plotted based on the number of days after start of GCV or PBS
treatment.

Flow cytometry
For analysis of YFP, aSMA-RFP, and FAP immunolabeled cells from the tumors of KTCY;
aSMA-RFP mice, the tumors were minced and digested in collagenase IV (4 mg/mL) and
dispase (4 mg/mL) in DMEM media for 1 hour at 37°C. Digested tissues were then filtered
through a 70 um mesh followed by a 40 um mesh, centrifuged, and incubated in ACK lysis
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buffer for 3 minutes at room temperature. Prior to staining, spleen was minced and filtered
through a 40 um mesh and both spleen and bone marrow were incubated in ACK lysis
buffed for 3 minutes at room temperature. FAP and its corresponding isotype antibody were
conjugated with Zenon Alexa Fluor 647 Rabbit IgG labeling kit according to manufacturer’s
instructions. Samples were stained with antibody and fixable viability dye eFluor 780 in
FACS buffer for 30 minutes on ice followed by washing prior to analysis on a BD FACS Aria.
For analysis of KPC tumors, tumors were digested and stained with fixable viability dye as
described above for KTCY; aSMA-RFP mice. For sorting experiments, samples were
analyzed and sorted on a BD FACS Aria. Unstained and single-stained samples were used
for compensation controls. Data analysis was performed in FlowJo software (TreeStar, Inc).
Details on the antibodies, source, and dilution are listed below:
Antibody

Source

Cat#

Dilution

Assay

Mouse monoclonal CD45-

Biolegend

109820

1:200 in 2%

FACS

Pacific Blue

FBS

Rat monoclonal CD31-

BD

AlexaFluor 647

Biosciences

Fixable Viability Dye eFluor

Ebiosciences

780
Rabbit polyclonal anti-FAP

Abcam

563608

1:100 in 2%

FACS

FBS
65-0865-

1:1000 in 2%
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FBS

ab28244

1:100 in 2%

FACS

FACS

FBS
Zenon Alexa Fluor Rabbit IgG
Labeling Kit

Thermo Fisher

Z25308

1:10 in 2%
FBS

FACS

ScRNA sequencing
Pancreatic tumors of KPCY, KPCY; aSMA-RFP, and KTCY; aSMA-RFP mice aged between
43 to 291 days were processed to obtain single cell suspension (see flow cytometry method
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section). 4 KPCY tumors were stained with a live cell dye, CD45, and CD31. One KTCY;
aSMA-RFP tumor was stained with a live cell dye and FAP. 3 KPC mice were stained with
live cell dye. The tumors were then sorted on a BD FACS Aria into one of 4 populations after
live cell gating: unfractionated, TN- CD45-YFP-CD31-, aSMA+, or FAP+. scRNA-seq on these
samples was conducted at the MDACC Advanced Technology Genomics Core. Single cell
Gel Bead-In-Emulsions (GEMs) generation and barcoding, post GEM-RT cleanup and cDNA
amplification, library construction and Illumina-ready sequencing library generation were
prepared by following the manufacturer’s guidelines. High Sensitivity dsDNA Qubit kit was
used to estimate the cDNA and library concentration. HS DNA Bioanalyzer was used for the
quantification of cDNA. DNA 1000 Bioanalyzer was used for the quantification of libraries. The
“c-loupe” files were generated by using Cell Ranger software pipelines following
manufacturer’s guidelines. Cells from unfractionated tumor were encapsulated using 10X
Genomics’ Chromium controller and Single Cell 3’ Reagent Kits v2. Following capture and
lysis, cDNA was synthesized and amplified to construct Illumina sequencing libraries. The
libraries from about 1,000 cells per sample were sequenced with Illumina Nextseq 500. The
run format was 26 cycles for read 1, 8 cycles index 1, and 124 cycles for read 2. scRNA-seq
data was processed by the Advanced Technology Genomics Core at MDACC.

Library Seurat (version 3.6.1), dplyr and cowplot were loaded into R to explore QC
metrics, filter cells, normalize data, cluster cells, and identify cluster biomarkers. To filter out
low-quality cells, a threshold with a minimum of 200 and a maximum of 4000-7000 genes
per cell was used. Cells with more than 10% of the mitochondrial genome were also
removed for further analysis. To remove the influence of technical characteristics from
downstream analyses, “sctransform” package was used for normalization. “RunUMAP”
function was used for clustering the cells. “FindAllMarkers” function was used to identify the
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specific markers for each cell cluster. “DoHeatmap” function was used to show the top
genes in each cluster. “VlnPlot” function was used to show expression probability
distributions across cell clusters of the genes we selected to assign the cell type identity,
and the genes that we were interested in.

CyTOF analysis
Pancreata from healthy, KPC, and KTC mice were processed to obtain single cell suspension
(see flow cytometry method section). For staining, 1.5x106 cells were stained first with
antibodies for surface markers in 0.5% BSA in PBS. Foxp3/Transcription Staining Buffer Set
(eBiosciences) was used for permeabilization for intracellular staining in accordance with the
manufacturer’s protocol. Samples were permeabilized and each sample barcoded using the
Cell-ID 20-plex Pd Barcoding Kit (Fluidigm) in accordance with the manufacturer’s guidelines.
Metal-conjugated antibodies were obtained from the MDACC North Campus Imaging and
Flow Cytometry Core. All unconjugated antibodies were conjugated in accordance with the
MaxPAR antibody conjugation kit (Fluidigm Sciences). Samples were analyzed with a CyTOF
2 mass cytometer (Fluidigm). FCS files were normalized using element beads and
debarcoding performed using Cytobank. Samples were concatenated and downsampled
(10,000 cells for plots of all cells and 2,000 cells for plots of CD31-EpCAM-CD45- cells) in
order to have equal representation across all samples. tSNE analysis was performed using a
custom-written MATLAB r2019a algorithm (Mathworks). Positive cell populations were gated
based on samples not stained with antibodies and overlaid with tSNE plots in FlowJo.
Antibody
Mouse

Source
monoclonal BioLegend

anti-Cytokeratin(pan)-

Cat#

Dilution

Assay

628602

1:250 in 0.5% CyTOF
BSA

153Eu
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Hamster

monoclonal DVS-Fluidigm

3152004B

anti-CD3e-152Sm

1:142.86

in CyTOF

0.5% BSA

Rat monoclonal anti- DVS-Fluidigm

3158018B

CD324/E-cadherin-

1:100 in 0.5% CyTOF
BSA

158Gd
Rat monoclonal anti- DVS-Fluidigm

3165013B

CD31-165Ho
118201

CD326 (Ms)-174Yb
monoclonal DVS-Fluidigm

3089005B

1:200 in 0.5% CyTOF
BSA

Rat monoclonal anti- DVS-Fluidigm

3148003B

CD11b-148Nd

1:400 in 0.5% CyTOF
BSA

monoclonal DVS-Fluidigm

3156023A

anti-Vimentin-156Gd

type

1:200 in 0.5% CyTOF
BSA

Rabbit polyclonal anti- EMD
Pro-collagen

1:500 in 0.5% CyTOF
BSA

anti-CD45(Ms)-89Y

Mouse

in CyTOF

0.5% BSA

Rat monoclonal anti- BioLegend

Mouse

1:333.33

ABT257

I-

1:100 in 0.5% CyTOF
BSA

162Dy
Mouse

monoclonal R&D

MAB1420

BSA

anti-aSMA-143Nd
Rabbit polyclonal anti- Abcam

ab28244

FAP-173Yb
Rabbit

monoclonal Abcam

anti-FSP1/S100A4-

1:200 in 0.5% CyTOF

1:25

in

0.5% CyTOF

in

0.5% CyTOF

BSA
ab220213

1:25
BSA

171Yb
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Rat monoclonal anti- eBiosciences

14-1401-82

CD140a/PDGFRα-

1:50

in

0.5% CyTOF

in

0.5% CyTOF

BSA

159Tb
Rat monoclonal anti- eBiosciences
CD140b,

14-1402-82

PDGFRβ-

1:50
BSA

175Lu

Histopathological scoring
Mouse tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, and
sectioned at 5 μm thickness. Sections were processed for hematoxylin and eosin (H&E)
staining, Masson’s trichrome staining (MTS) using Gomori’s Trichome Stain Kit (38016SS2,
Leica Biosystems), or picrosirius red (Direct Red 80, Sigma-Aldrich). Histopathological
assessments were conducted in a blinded fashion by scoring H&E-stained sections for relative
percentages of the listed histopathological phenotypes. A weighted histology score was then
applied to the percentages as follows: for tumors with less than 5% normal tissue two points,
else zero points; greater than 30% PanIN or ADM tissue two points, else zero points; cancer
area greater than 30% 4 points, else zero points; poor differentiated PDAC area greater than
30% 5 points, else zero points; and necrosis area greater than 5% 6 points, else zero points.
The weighted scores were then summed for each animal to be interpreted as a higher value
meaning worse histopathology. Images were obtained with a Leica DM 1000 LED microscope
using a 20x objective and an MC120 HD Microscope Camera with Las V4.4 Software (Leica).
Tumor scores for orthotopic tumors were evaluated based on H&E sections of the entire
pancreas and attributed a score on a scale from 1 (minor involvement) to 4 (extensive
involvement).

Immunofluorescent labeling and immunohistochemistry
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Formalin-fixed,

paraffin-embedded

(FFPE)

sections

were

processed

for

immunohistochemical (IHC) staining as previously described, after citrate-based antigen
retrieval (pH=6)60. Staining for αSMA was performed with M.O.M. kit (Vector Laboratories)
following the manufacturer's instructions. For all stainings, counterstaining with hematoxylin
was performed and DAB positivity was examined in ten visual fields at 200× magnification.
For αSMA IHC on mouse tumor sections, immunoreactive score (IRS) were obtained from the
sum of distribution and intensity scores for each section, established on a scale of 1 to 4
. FAP immunohistochemistry was performed using FFPE mouse tumor sections and imaged
identically as the multiplex panel (see below). Pseudocolored images with FAP-520 channel
being colored brown and the DAPI channel colored blue on a white background were used
for the scoring. The stromal region was scored on a scale of 0-3 for the density of FAP+
fibroblasts in each image. The scores were averaged for each mouse and presented in Figure
10C. FAP staining on human tissues was performed after citrate-based antigen retrieval
(pH=7.4). Staining for αSMA was performed with M.O.M. kit (Vector Laboratories) following
the manufacturer's instructions. For αSMA and FAP double immunofluorescence in human
FFPE sections, secondary anti-sheep Alexa Fluor 488 and anti-mouse Alexa Fluor 594
antibodies were incubated for 30 min at RT. Tissues were imaged at 20x magnification with
a Zeiss Axio Observer Z1 inverted fluorescent microscope. Analysis of 6 fields of view (20x)
were scored per sample and averaged for Figure 6C. For Desmin/CD31 co-staining FFPE
sections underwent citrate antigen retrieval (pH=6) for 30 minutes at 98C. They were then
blocked with 4% cold water fish gel in TBST for one hour at room temperature and stained for
48 hours in primary at 4C. Slides were then washed and placed in secondary for 1 hr at room
temperature. They were then washed and DAPI added to stain the nucleus of the cells in the
tissue section Figure 11D.
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Antibody

Source

Cat#

Dilution

Assay

Opal

Opal
Dilution

Rabbit polyclonal

Abcam

ab53066

anti-FAP
Mouse

1:100 in

IHC

10% BSA
DAKO

M0851

monoclonal anti-

1:200 in

Opal

1:50

520
IF

0.5% BSA

aSMA
Rabbit polyclonal

Abcam

ab53066

anti-FAP
Rat monoclonal

1:200 in

IF

0.5% BSA
Dianova

DIA310

anti-CD31

1:50 in

IF

Cold
water Fish
Gelatin

Mouse

DAKO

M0852

monoclonal anti-

1:200 in

IF

0.5% BSA

aSMA

Mouse
DAKO
monoclonal antiaSMA
Rabbit polyclonal Abcam
Desmin

Biotinylated
Rabbit antiSheep IgG
Alexa Fluor 488
Goat anti-Rat
Alexa Fluor 568
Goat anti-Rabbit

Vector
Laboratorie
s
Invitrogen
Invitrogen

M0651

1:100 in
10%
BSA
ab1520 1:50 in
0
Cold
Water
Fish
Gelatin
BA-6000 1:200 in
1% BSA

IHC

A11006

IF

A11011

1:100 in
1% BSA
1:100 in
1% BSA

IF

IHC

IF
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Alexa Fluor 488
Donkey antisheep
Alexa Fluor 594
Goat anti-mouse

Invitrogen

A11015

1:200 in
1% BSA

IF

Invitrogen

A11032

1:200 in
1% BSA

IF

Multispectral imaging of multiplex stained tissue sections
The multiplex staining procedures, spectral unmixing and cell segmentation using the Nuance
and inForm imaging softwares were previously published60. Multiplex stained slides were
imaged with the Vectra Multispectral Imaging System, using Vectra software version 3.0.3
(Perkin Elmer). Each tissue section was scanned in its entirety using a 4x objective, and up
to 50 cancer regions (at 20x) were selected for multispectral imaging using the Phenochart
software (Perkin Elmer). Each multiplex field was scanned every 20 nm of the emission light
spectrum across the range of each emission filter cube. Filter cubes used for multispectral
imaging were DAPI (440-600 nm), FITC (520 nm-680 nm), Cy3 (570-690 nm), Texas Red
(580-700 nm) and Cy5 (680-720 nm). Multispectral images from single marker stained slides
with the corresponding fluorophores were used to generate a spectral library using the Nuance
Image Analysis software (Perkin Elmer). The library contained the emitting spectral peaks of
all fluorophores and was used to unmix each multispectral image (spectral unmixing) to its
individual 8 components by using the inForm 2.4 image analysis software. All spectrally
unmixed image cubes were subsequently segmented into individual cells based on the
nuclear DAPI counterstain. For the immune cell population analysis, all spectrally unmixed
and segmented images were analyzed using the inForm phenotyping algorithm. This allows
for the individual identification of each DAPI-stained cell according to their pattern of
fluorophore expression and nuclear/cellular morphological features. Cells were phenotyped
into eight different classes according to the markers they expressed: CD3+ T cells (CD3+), Teff
cells (CD3+CD4+Foxp3-), cytotoxic T cells (CD3+CD8+), Treg cells (CD3+CD4+Foxp3+),
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macrophages (CD11b+), proliferating cells (Ki67+), cancer cells (CK8+), and other cells
(negative for all markers). Antibodies source and dilution:
Antibody

Source

Cat#

Dilution

Assay Opal

Opal
Dilution

Rabbit

Abcam

ab16669

in TSA

Opal 620

1:200

in TSA

Opal 650

1:100

in TSA

Opal 540

1:100

14-4771-

1:2,000 in TSA

Opal 570

1:50

80

1% BSA

ab133357

1:40,000

TSA

1:50

monoclonal

1:750
1% BSA

anti-CD3
Rabbit

Cell Signaling

25229S

monoclonal

1:200
1% BSA

anti-CD4
Rabbit

Cell Signaling

98941S

monoclonal

1:800
1% BSA

anti-CD8a
Rat

eBiosciences

monoclonal
anti-Foxp3
Rabbit

Abcam

monoclonal

in

anti-CD11b

Cold

TSA

4%

Coumarin

Water
Fish
Gelatin
Rat

University

of Troma-1

monoclonal

Iowa

anti-CK8

Developmental

1:50

in TSA

Opal 520

1:850

1% BSA
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Studies
Hybridoma Bank
Rabbit

Thermo Fisher

monoclonal-

RM-9106-

1:400

S

1% BSA

ab53066

1:100

in TSA

Opal 690

1:50

in IHC

Opal 520

1:50

Ki67
Rabbit

Abcam

polyclonal

10% BSA

anti-FAP

Rabbit-onRodent
HRPPolymer
Polink-1
HRP RatNM for
DAB Bulk
Kit
Mouse-onMouse
HRPPolymer
Polink-1
HRP Goat
for DAB
Bulk Kit
4plus
Streptavidin
HRP
Polymer

BioCare

RMR622L -

TSA

GBI Labs

D35-110

-

TSA

BioCare

MM510L

-

IHC,
TSA

GBI Labs

D33-110

-

TSA

BioCare

HP604H

-

IHC

Global gene expression profiling
Total RNA was also isolated from tumors of age-matched KTC; αSMA-TK, and KTC; FAP-TK
mice (n = 3 mice per in each group), that were administrated with GCV or PBS. RNA extraction
was carried out using the QIAGEN RNeasy Mini Kit and submitted to the Microarray Core
Facility at MD Anderson Cancer Center. Gene expression analysis was performed using
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Affymetrix MTA 1.0 Genechip. The Limma package from R Bioconductor was used for
quantile normalization of expression arrays and to analyze differential gene expression
between the TK groups (KTC; aSMA-TK and the KTC-FAP-TK groups) and their respective
control (KTC; aSMA-TKcontrol and KTC; FAP-TKcontrol) groups (p ≤ 0.05 and fold change ≥ 1.2).
Analyses of differentially expressed pathways between the TK and control groups were
performed using Gene Set Enrichment Analysis (GSEA). Microarray data from KTC; aSMATK GEM were previously deposited at Gene Expression Omnibus under accession number
GSE52812. Gene expression microarray data from KTC; FAP-TK GEM was deposited in GEO
(reviewer’s link: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120577).

Statistical analyses
The statistical tests used for the comparative analyses presented are listed in the figure
legends. Statistical analyses were carried out using GraphPad Prism (GraphPad Software
version 8). Kaplan-Meier plots were used for survival analysis and the log rank Mantel-Cox
test was used to evaluate statistical differences with GraphPad Prism. Error bars represent
standard error of the mean unless specified in the figure legends. Statistical significance was
defined as P < 0.05.
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Chapter 3

Cancer Associated Fibroblast Heterogeneity Throughout Cancer Progression

This work was done in collaboration with Drs. Kathleen McAndrews, Julienne Carstens,
Valerie LeBleu, Sujuan Yang, and Patricia Phillips

27

Summary
PDAC is a progressive disease that consists of stages43–45. Precancerous pancreatic lesions
are known as pancreatic intraepithelial neoplasia or PanIN. Once precancerous lesions
become invasive, they are considered cancer. The KPC and KTC murine models commonly
used by cancer biologists incorporate common mutations often seen in PDAC patients to
study PDAC75,76. These two GEMMs follow the similar trends of tumorigenesis as human
PDAC. Furthermore, the characteristic desmoplasia associated with PDAC is recapitulated,
allowing scientists to study CAF populations within PDAC to understand their heterogeneity
throughout cancer progression. This chapter describes the heterogeneity of CAFs in PDAC
using scRNAseq and CyTOF. We used transcript and protein expression of CAFs defined by
common mesenchymal markers to assess the heterogeneity of CAFs throughout pancreatic
cancer progression.

Introduction
The presence of different CAFs has been correlated with patient survival in PDAC50,55,58.
However, the inconsistencies with CAF definitions, tumor staging at which tumors are
analyzed in both human and mouse, and the potential differences in tumors with different
genotypes has led to convolution of results. While aSMA expression in patient samples has
been correlated with both prolonged and decreased survival, presence of FAP CAFs has
been associated with decreased patient survival in PDAC79. An outstanding question in the
field remains as to the dynamic presence of CAFs throughout PDAC progression. Most
cases of pancreatic cancer are diagnosed at late stages80. Therefore, understanding the
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stages at which
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Figure 1. Distinct CAFs populations are identified in pancreatic tumors
(A) UMAP projection of cell populations in KPC pancreatic tumors as
determined by scRNAseq (n=8 mice; 23,723 cells; left panel). UMAP projection
of the digitally selected fibroblast cluster in KPC mice identifying 6 distinct
fibroblast populations (n=8 mice; 5,663 cells; right panel). (B) UMAP projection
(left) and heatmap key of Acta2 and FAP transcripts in KPC tumors. (C) UMAP
projection of subpopulations of cCAF cluster identified in (A). (D) UMAP
projection (left) and heatmap key of Acta2 and FAP transcripts in cCAF cluster.
(E) Violin plots of Acta2 and FAP expression levels in cCAF subsets.

Single Cell RNA sequencing identifies 6 unique CAF clusters in KPC mice
We began our study by assessing the transcriptional landscape of KPC tumors. Similar to
previously published literature, we found unique clusters of epithelial, endothelial, immune,
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pericyte, populations (Figure 1A, left panel). When we analyzed the CAF cluster at a higher
resolution, we found 6 unique CAF clusters defined a-fCAF (Figure 1A, right panel).
Although literature suggests that aSMA and FAP CAFs may have unique functions, groups
have previously published that aSMA and FAP clustered together transcriptomically in both
human and murine PDAC scRNAseq datasets81,82. Therefore, we sought to understand in
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Figure 2. αSMA and FAP exist largely as distinct
populations in human PDAC
(A) UMAP projections and heatmap key of ACTA2 and
FAP-expressing CAFs from human PDAC samples.
scRNA-seq data from Peng et al. (Peng et al., 2019) was
reanalyzed to overlay ACTA2 and FAP-expressing CAFs.
Fibroblast clusters were digitally selected by expression of
mesenchymal genes COL1A1, COL1A2, DCN and PDPN.
(B) UMAP projections and heatmap key of ACTA2 and
FAP-expressing CAFs (cells isolated based on lack of
EpCAM, CD31, and CD45 protein expression) from human
PDAC samples. scRNA-seq data from Elyada et al.
(Elyada et al., 2019) was reanalyzed to overlay ACTA2
and FAP-expressing CAFs.

the same CAF clusters, we noted that
aSMA and FAP were rarely expressed
in the same cells, and the two
populations had differences in their
prevalence within the cCAF
subclusters (Figure 1D-E).
Upon transcriptomic
characterization of aSMA+ and FAP+
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CAFs in KPC mice, we
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Figure 3. αSMA and FAP label distinct CAFs populations in PDAC
CyTOF analysis of KPC and KTC mice. (A) Abundance of CD45+ cells, EpCAM+
cells, CD31+ cells, and triple negative (TN, CD45-EpCAM-CD31-) cells in KPC mice
(left panel). tSNE projection of CD45+, EpCAM+, and CD31+ cells in KPC mice (right
panel). (B-C) tSNE projection of fibroblast marker expression in TN cells with color
coded key (B, left panel) and relative abundance of fibroblast subpopulations (B,
right panel) in KPC mice. (C) Abundance of CD45+ cells, EpCAM+ cells, CD31+
cells, and triple negative (TN, CD45-EpCAM-CD31-) cells in KTC mice (left panel).
tSNE projection of CD45+, EpCAM+, and CD31+ cells in KTC mice (right panel). (D)
tSNE projection of fibroblast marker expression in TN cells with color coded key
(D, left panel) and relative abundance of fibroblast subpopulations (D, right panel)
in KTC mice. (E-F) αSMA+ and FAP+ cell abundance in PDAC. tSNE projections
and relative abundance of αSMA+FAP-, αSMA-FAP+, and αSMA+FAP+ cells in KPC
(E) and KTC (F) mice. n=2 mice in each group.

CyTOF confirms the presence of CAFs in KPC and KTC mice
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ScRNAseq has been used by

Figure 4
A

Col1a1

Col1a2

Col1a1

Col1a2

many groups to assess the
heterogeneity of fibroblasts in

Vim

Col3a1

Vim

Col3a1

PDAC, but few studies have used
comprehensive protein analysis

Pdpn

Tagln

Pdpn

Tagln

to confirm their findings81,82.
Therefore, we developed a

Fap

S100a4

Fap

S100a4

CyTOF panel of common
mesenchymal markers to assess

Acta2

Pdgfra

Acta2

Pdgfra

the stromal composition within
murine PDAC models. EpCAM+
epithelial cells, CD31+ endothelial

Pdgfrb

Pdgfrb

a b c d e f

cells, and CD45+ immune cells
were detected in the tumors by
a b c d e f

mass cytometry in KPC mice
Figure 4. Expression of fibroblast and pericyte genes of
CAFs in KPC tumors
(A) UMAP projection of cell populations in KPC CAFs with
the indicated relative gene expression. Violin plots of the
same genes indicating relative gene expression by cluster.

(Figure 3A). Cells that were
negative for EpCAM, CD31, and
CD45 were called our triple negative

(TN) population and considered our fibroblast population. We then assessed the relative
abundance of our fibroblast populations and found that the majority of CAFs in KPC mice
express aSMA, PDGFRa, and FSP1. Subsets such as PDGFRb and FAP were far scarcer
(Figure 3B). To ensure our findings were not specific to our model, we also assessed KTC
mice, and found similar patterns. Epithelial cells, endothelial cells, and immune cells were
readily found in the KTC mice as well as the KPC model (Figure 3C). The CAF composition
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in KTC mice was similar to KPC mice (Figure 3D). In both models we found that aSMA and
FAP were rarely co-expressed in CAFs (Figure 3E-F).
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Figure 5. Protein analysis of putative CAF markers in KPC mice, KTC
mice, and human PDAC
(A-B) tSNE projections of CAF markers expressed in TN cells in KPC (A)
and KTC (B) mice as determined by CyTOF analysis. KPC, n=2 mice;
KTC, n=2 mice. (C) Representative immunofluorescence image of αSMA
(red) and FAP (green) in human PDAC (left panel). Scale bar, 100 µm.
Quantification of the percentage of FAP and αSMA expressing cells out of
the total pixel coverage in two human PDAC patient samples (right panel)

most distinct populations in
KTC and KPC tumors
(Figure 4, 5A, 5B). When
comparing the transcripts
of fibroblast populations to

the protein expression of populations analyzed by CyTOF, we found several discrepancies.
The relative abundance of Acta2 was much lower when assessing the transcript of the CAF
subset as opposed to the aSMA protein as analyzed by CyTOF (Figure 4, 5A, 5B).
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Additionally, Acta2 and Fap were expressed in the same clusters in scRNAseq. However,
CyTOF analysis showed that aSMA and FAP were rarely co-expressed, and existed in
different cell clusters. To understand whether our protein findings were clinically relevant, we
performed immunohistochemistry on two human PDAC patient samples and found minimal
overlap between aSMA and FAP expressing CAFs (Figure 5C).

aSMA+ and FAP+ CAFs are most abundant in endpoint KPC tumors
Upon discovering discrepancies between the transcript and protein expression of putative
Figure 6
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Figure 6. Protein analysis of putative fibroblast markers in
healthy pancreases
(A) Abundance of CD45+ cells, EpCAM+ cells, CD31+ cells,
and triple negative (TN, CD45-EpCAM-CD31-) cells (left panel)
as determined by CyTOF analysis of pancreata of non-tumor
bearing mice. n=2 mice. tSNE projection of CD45+, EpCAM+,
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(Figure 6A). The stroma made up
~24% of the cells in healthy
pancreas (Figure 6B), and
expression of our putative fibroblast
markers in the stroma of healthy

pancreas was consistent with our end stage KPC and KTC tumors (Figure 6C). Importantly,
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the minimal overlap
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Figure 7. Fibroblast clusters expressed throughout KPC tumor
progression
UMAP projections of 6 late, 3 middle, and 5 early stage KPC tumors.
Tumors were defined by gross anatomy. Late-staged tumors
encompassed the entirety of the pancreas. Middle-staged tumors had
~50% soft tissue. Early- staged tumors had nodules of tumors with most
of the pancreas consisting of soft tissue.

diagnosed with end stage
pancreatic cancer at first
diagnosis, our results
indicating that aSMA and

FAP CAFs are distinct populations that may be more transcriptionally active in end stage
tumors encouraged us to move forward with the functional assessment of aSMA and FAP
CAFs due to the incredible clinical relevance of our findings to human PDAC.
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Interpretation of Findings
We characterized the stromal makeup of two GEMMs. Immune cells were the major
population in KPC tumors. Meanwhile the stromal cells were the dominant population of
cells in the TME of KTC tumors. The discrepancies in the amount of stroma between models
could simply be due to the differences in genotype of the cancer. However, with the data
collected from this study, we cannot currently conclude that the genotype of the tumors was
the only differences leading to the discrepancies we see between the two GEMMs. By
protein expression aSMA+ CAFs represented the most abundant mesenchymal subset of
the markers assessed in both GEMMs. FAP+ CAFs made up a small percentage of
fibroblasts but was also the most distinct population from aSMA+ CAFs. Although protein
expression of aSMA and FAP expressing CAFs revealed two decisively distinct populations,
in our transcriptional analysis, using scRNAseq, we found that aSMA and FAP expressing
CAFs clustered into the same CAF cluster. However, upon further assessment we confirmed
that the CAFs expressing aSMA and FAP transcripts were distinct in both mouse and
human PDAC. Finally, we addressed whether the heterogeneity of CAFs was tumor stage
dependent. Protein expression of CAFs remained consistent in healthy, KPC, and KTC
pancreas. Transcriptionally, however, the CAF subsets in KPC tumors undergo dynamic
shifts throughout tumor progression. Our findings unraveled CAF heterogeneity in two
GEMMs, confirming the existence of distinct fibroblast populations with potential clinical
relevance, and revealing the necessity of utilizing both transcriptional and protein-based
analysis in the characterization of stroma in PDAC.

Potential Pitfalls and Alternative Approaches
Single cell assessment such as CyTOF and scRNAseq fails to present a full picture of tumor
heterogeneity. The processing of the tissues may have skewed the populations that we
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were able to assess. Combining imaging mass cytometry with RNA in situ hybridization
would have given us a more comprehensive idea of the stromal makeup while preserving
the tumor architecture, allowing us to not only identify CAF populations, but also where
different CAFs reside in the tumor in relation to cancer cells, immune cells, and vasculature.

Future Directions
We will follow up on the findings that tumors of different genotypes have different amounts
of stroma. We will use CyTOF to analyze the tumors of patients with different genetic
mutations to understand how PDAC genetics influences stromal composition. Furthermore,
with the thorough characterization of CAF populations in PDAC mouse models complete, it
would be interesting to understand how the dynamic changes seen throughout PDAC
progression in murine CAF subsets correlate to tumor staging and survival in patient
cohorts. We would use TSA immunohistochemistry multiplexing, CyTOF, and scRNAseq on
patient samples of different stages to understand how the protein and transcript expression
of common mesenchymal markers can help us determine clinical targets of CAFs in PDAC.
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Chapter 4

Functions of Cancer Associated Fibroblasts in PDAC

This work was done in collaboration with Drs. Kathleen McAndrews, Sujuan Yang, Xiaofeng
Zheng, Julienne Carstens, Hikaru Sugimoto, Valerie LeBleu, Pedro Correa de Sampaio,
Patricia Phillips, Judith Kaye, and Michelle Kirtley
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Summary
After we found that aSMA+ and FAP+ CAFs represented the two most distinct populations in
our PDAC models, confirmed the distinction of the populations in human PDAC, and
discovered aSMA+ and FAP+ CAF transcripts to be upregulated in late stage KPC tumors,
we next assessed the functions of aSMA+ and FAP+ CAFs in vivo. Our lab previously
published a novel GEMM in which KTC mice were crossed with transgenic mice expressing
a viral thymidine kinase driven by the aSMA promoter (KTC; aSMAtk). In this model, mice
are treated with ganciclovir (GCV) on day 28 when the mice have developed PanIN lesions.
Cells expressing the aSMAtk phosphorylate the GCV, creating nucleotide analogs. These
analogs are incorporated into the DNA and halt replication, leading to the prevention of
accumulation of aSMA+ CAFs in the TME. We developed a similar GEMM in which KTC
mice were crossed with transgenic mice expressing a viral thymidine kinase driven by a FAP
promoter (KTC; FAPtk). We began treating all GEMM when they had developed PanIN
lesions.
We confirmed that FAP and aSMA expressing fibroblasts are distinct as when either
population was depleted from the TME, the other remained unchanged. In our functional
studies aSMA CAFs were primarily tumor restraining and depletion led to poorer survival in
KTC mice. However, we found that depletion of FAP+ CAFs from the tumor
microenvironment led to better tumor histology and prolonged survival of KTC mice.
Altogether, our data from this chapter reveals the existence of two distinct CAF populations
with opposing roles on PDAC progression and GEMM survival.

Introduction
aSMA+ and FAP+ CAFs have been extensively studied in PDAC48,50,79,83,84. Early studies
indicated a tumor promoting role for CAFs in the TME. However, our lab and others found
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that when aSMA expressing CAFs were depleted from the TME, tumor progression
significantly accelerated leading to poorer outcomes in mouse models50,83,84. aSMA was also
correlated with prolonged patient survival in patient cohorts. However, other studies have
since found that aSMA CAFs correlate to decreased survival in patient cohorts79. Groups
assessing the functions of FAP+ CAFs in PDAC found that FAP expression in tumors
correlates to poorer clinical outcomes56,85. Furthermore, depletion of FAP+ CAFs led to
inhibition of PDAC in KPC mice. The differences in mouse models, treatments, processing
techniques, and other variables has made it hard to compare studies from different groups.
In an effort to gain a clear picture of the contributions of aSMA+ and FAP+ CAFs to the TME,
we compared KTC; aSMATK and KTC; FAPtk GEMM cohorts.

Depletion of aSMA+ and FAP+ CAFs have opposing roles on PDAC progression
Prior to beginning our functional studies, we characterized our healthy FAPtk mice. As
studies have previously shown that targeting FAP in mice can result in cachexia, we sought
to ensure there would not be adverse effects of depleting FAP CAFs in mice that were
unrelated to their roles in the TME86. We saw no changes in the body weight of non-tumor
bearing FAPtk mice treated with GCV (Figure 8A). Furthermore, we did not see any
difference in the pancreas, spleen, quadricep or gastrocnemius muscles when mice were
treated with ganciclovir (Figure 8B). Splenic analysis did not indicate depletion of FAP+
cells. (Figure 8C).
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(A) Body weight measurement over time in non-tumor bearing FAPTK mice administered GCV. FAP control, n = 3; FAP depleted, n = 4
mice. (B) Pancreas, spleen, quadriceps muscle (QM), and
gastrocnemius muscle (GM) weight at end point. (C) Gating strategy
and quantification of FAP+ cells in the spleen. An unpaired twotailed t-test performed. ns: not significant.

KTC; FAPtk and KTC; aSMAtk
lines, respectively. As we saw
in our previous publication,

when aSMA+ cells were depleted from the tumor microenvironment there was a decrease in
the survival of the mice. However, when FAP+ cells were depleted from the tumor
microenvironment, survival of mice was prolonged compared to control (Figure 9A). As we
previously had found that tumor histology was poorer when aSMA+ cells were depleted in
orthotopically implanted KPC tumor models, we performed orthotopic implantations in FAPtk
mice. When FAP+ cells were depleted from the tumor there was significantly better histology
as shown represented by a lower histology weighted score (Figure 9B). We performed
H&E and immunohistochemistry on KTC; aSMAtk and KTC; FAPtk for aSMA and FAP
(Figure 9C). KTC; aSMAtk mice presented with more necrotic tissue. Meanwhile KTC;
FAPtk mice had more normal pancreas. As expected, in KTC; aSMAtk tumors aSMA protein
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expression was significantly lower than in control mice. Similarly, in KTC; FAPtk tumors FAP
protein expression

Figure 9
A
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Figure 9. αSMA+ and FAP+ CAFs have opposing roles in PDAC progression
(A) Survival curves of KTC mice after start of treatment with GCV or PBS. αSMA
control, n=15; αSMA depleted, n=19; FAP control, n=10; FAP depleted, n=7. (B)
Representative H&E staining of pancreas tumor sections of orthotopically
implanted KPC689 cells in FAP-TK mice (left panel). Tumor score evaluated
based on H&E staining (right panel, n=4 mice per group). The mean ± s.e.m. is
depicted with a Mann-Whitney test performed comparing control to depleted mice.
(C) Representative micrographs of H&E (top panel), αSMA (middle panel) or FAP
(bottom panel) immunolabeled KTC pancreas tumor sections. Scale bar: 100 µm.
(D) Relative percentages of each tumor histological phenotype (left panel). αSMA
control, n=14; αSMA depleted, n=11; FAP control, n=7; FAP depleted, n=7.
Quantification of αSMA (middle panel) and FAP (right panel) density scores.
αSMA control, n=8; αSMA depleted, n=7; FAP control, n=6; FAP depleted, n=7.
One-way ANOVA with Tukey’s multiple comparisons test was performed
comparing control to depleted mice. * p < 0.05, ** p < 0.01, **** p < 0.001.
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Depletion of aSMA+ and FAP+ CAFs have no effects on the collagen deposition in PDAC
To address changes in the TME that could support the changes in survival observed when
CAFs were depleted from the TME, we used Sirius Red and MTS to assess changes in
collagen deposition when CAFs are depleted. However, we found no significant differences
Figure 10
A

in collagen

⍺SMA control

⍺SMA depleted

FAP control

FAP depleted

Sirius Red

deposition in KTC;
aSMAtk or KTC;

MTS

FAPtk tumors
(Figure 10A, 10C).

D

*

15
10
5
0

αSMA
αSMA
control depleted

⍺SMA control

15

*

10
5
0

FAP
FAP
control depleted

⍺SMA depleted

C

60

Sirius Red Score

20

Weighted Histology Score

B

Weighted Histology Score

Utilizing a weighted
histology score in

ns
40

ns

20
0

A
A
M l M d
αS ntro αS ete
pl
co
de

FAP control

which a higher score

P
P l
FA tro FA ed
n
et
co
pl
de

represents more

FAP depleted
% Desmin+ Area/
Visual Field (20x)

Desmin/CD31/DAPI

20
15

ns
ns

poorly differentiated

10

tumors, we

5
0

P
P
A
A
M l M d FA ol FA d
r
αS ntro αS te
te
nt
ple
ple
co
co
de
de

Figure 10. Tumor microenvironment changes with αSMA and FAP depletion
in KTC tumors
(A) Sirius Red and MTS staining of KTC tumors. n=7 mice per group. (B)
Quantification of weighted histology of KTC tumors. n=7 mice per group. (C) Sirius
Red quantification of KTC tumors. n=7 mice per group. (D) Representative
immunofluorescence CD31 (green) and desmin (red) co-staining of KTC tumors
(left panel, scale bar: 100 µm). Desmin pericyte tissue coverage in KTC tumors
(right panel). The mean ± s.e.m. is depicted with an unpaired t-test performed
comparing control to depleted mice. αSMA control, n=4 mice; αSMA depleted, n=5
mice; FAP control, n=4 mice; FAP depleted, n=4 mice. One-way ANOVA and
Welch’s two-tailed t-test comparing control to depleted mice performed. * p < 0.05,
** p < 0.01, **** p < 0.0001 ns: not significant.

established that
KTC; aSMAtk
tumors had higher
weighted
histology scores
than control while
KTC; FAPtk mice

had lower scores (Figure 10B). Finally, we evaluated whether our depletion models were
leading to changes in vasculature or perivascular coverage. Desmin and CD31
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immunofluorescence confirmed that pericytes, vasculature, and perivascular coverage
remained unchanged when CAFs were depleted (Figure 10D).

Interpretation of Findings
In this chapter we uncovered two fibroblasts populations with opposing roles on PDAC
progression. Depleting aSMA+ cells from the TME resulted in shortened survival of KTC
mice and poorer histology. In direct contrast to KTC; aSMAtk mice, KTC; FAPtk mice had
prolonged survival with more normal pancreas present upon histological analysis. We define
for the first time two fibroblast populations with opposing functional contributions to PDAC.
aSMA+ CAFs represent a tumor suppressing population and FAP+ CAFs represent a tumor
restraining population in PDAC.

Potential Pitfalls and Alternative Approaches
Although we previously published that KPC; aSMAtk and KTC; aSMAtk models have
consistent results, in this study we only performed functional assessments of FAP+ and
aSMA+ CAFs using the KTC model. There may be differences in the functions of FAP+
CAFs in the KPC model. Alternatively, we could cross our mice to the KPC model to assess
whether our CAF populations are still opposing in the context of other common PDAC
genotypes.

Future Directions
Our functional study was focused on the two most distinct fibroblast populations we
assessed by protein expression in order to maintain clarity in the interpretation of the results.
However, understanding how other common fibroblast populations function in PDAC would
add great insight into the prognostic value of stromal composition. To this end, we will next
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us KTC; Vimentintk and KTC; FSP1tk models to assess how vimentin+ and FSP1+ CAFs,
respectively, functionally contribute to the tumor microenvironment.
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Chapter 5

Cancer Associated Fibroblasts Differential Roles in PDAC Immunity

This work was done in collaboration with Drs. Kathleen McAndrews, Sujuan Yang, Valerie
LeBleu, Xiaofeng Zheng, Julienne Carstens, Pedro Correa de Sampaio, Michelle Kirtley and
Patricia Phillips
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Summary
Once we had established the opposing roles of aSMA+ and FAP+ CAFs in the TME we
sought to understand the mechanism behind the poorer outcomes and better outcomes in
KTC mice when aSMA+ CAFs and FAP+ CAFs are depleted, respectively. We used
scRNAseq and microarray analysis to establish that aSMA+ and FAP+ CAFs expressed
unique transcripts. FAP+ CAFs were primarily associated with inflammatory responses.
However, aSMA+ CAFs expressed transcripts related to extracellular matrix remodeling. We
compared our clusters to the well-established myCAF, iCAF, apCAF clusters as defined by
Elyada et. al81. We found that although FAP+ CAFs express inflammatory transcripts, aSMA+
and FAP+ CAFs both cluster in the myCAF cluster. Finally, we assessed changes in the
tumor microenvironment as a whole when aSMA+ or FAP+ CAFs are depleted from KTC
tumors. We found that in KTC; FAPtk tumors, the top pathways downregulated were
immune related. Contrarily, in KTC; aSMAtk tumors the top pathways downregulated
compared to KTC controls were extracellular matrix related. Using multiplex
immunohistochemistry, we investigated changes in immune infiltrate when CAFs are
depleted in PDAC. We confirmed our previous finding that when aSMA+ CAFs are depleted
there is a decrease in the CD3+CD4+FoxP3-/ CD3+CD4+FoxP3+ ratio. We discovered that
CD11b+ myeloid cells are significantly decreased in KTC; FAPtk tumors. This chapter
establishes the primary roles of aSMA+ and FAP+ CAFs as extracellular matrix remodeling
and inflammatory, respectively, and characterizes CAFs as immune modulatory cells.

Introduction
A resurging area of interest in stromal biology is the crosstalk between CAFs and immune
cells50,53,56,57,87,88. It is very well accepted in TME research that CAFs have a role in shaping
the immune microenvironment. CAFs are known to secrete important factors for immune
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regulation such as LIF, IL1, IL6, and TGFB89. As immunotherapy continues to gain traction
in several cancers, PDAC remains one of the diseases with no curative therapeutic options
and little success of immunotherapies. Therefore, studies are focused on establishing the
immune regulatory functions of CAF subsets in order to augment immunotherapeutic efforts.
Thus far it has been documented that fibroblasts can be both immune stimulatory and
immune cell inhibiting11,12,42,90. In mouse models, depletion of aSMA+ CAFs led to an
increase in Tregs, a decrease in the CD3+CD8+: CD3+CD4+FoxP3+ ratio within the TME.
Interestingly, although depleting aSMA+ cells led to a more immunosuppressive TME, it
augmented aCTLA4 immunotherapy efficacy50. Alternatively, depleting FAP+ cells in the
TME led to an increase in cytotoxic T-cells and increase immune checkpoint blockade
efficacy in PDAC57. Although there are extensive studies supporting the importance of CAFs
in immune regulation, it is still not known exactly how CAF subsets uniquely affect immune
cells in PDAC.

aSMA+ and FAP+ fibroblasts express unique transcripts in PDAC
To establish the functions of aSMA+ and FAP+ CAFs we employed or KTCY; aSMARFP
mice. We stained the tumors with a FAP antibody conjugated to APC (Figure 11A). We
used the spleen to control for RFP positivity as there are few aSMA+ splenic cells then
performed FACS (Figure 11B). FACs analysis supported our findings that aSMA+ and FAP+
CAFs were distinct (Figure 11C). We isolated single positive RFP+ (aSMA+) and APC
(FAP+) cells to analyze by scRNAseq (Figure 11D).
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In our scRNAseq of aSMA+ and FAP+ CAFs, we found that aSMA+ and FAP+ CAFs
expressed unique transcripts (Figure 12A). Cluster analysis revealed 8 clusters in total
between aSMA+ and FAP+ CAFs. Solely aSMA+ CAFs were found in cluster 8 but rarely
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Figure 11. FACS gating strategy for sorting αSMA and FAP-expressing CAFs.
(A) Flow cytometry gating strategy for FAP in KTC mice. (B) Flow cytometry gating strategy for
endogenous YFP and RFP fluorescence in KTC mice. An unstained spleen was used as a negative
control.
(C-D) Abundance of αSMA+, FAP+, and YFP+ cancer cells in KTCY; αSMA-RFP tumors as evaluated
by FACS. (C) FACS plots defining αSMA+ CAFs, FAP+ CAFs, and YFP+ cancer cells. (D) FACS plots
of overall prevalence of αSMA+ and FAP+ cells.

seen in clusters 5, 6, and 7. FAP+ CAFs were most prevalent in clusters 0, 5, 6, and 7
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(Figure 12B). Heatmap analysis of aSMA+ and FAP+ CAFs supported our functional studies
establishing aSMA+ and FAP+ CAFs as unique and likely opposing CAF subsets (Figure
12C). In IPA network analysis aSMA+ CAFs were extracellular matrix remodeling and FAP+
Figure 12
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CAFs were inflammatory (Figure 12D).
aSMA+ and FAP+ CAFs have diverse roles in PDAC immunity
Network analysis revealed aSMA+ CAFs as ECM remodeling and FAP+ CAFs as
inflammatory. Therefore, we next used our scRNAseq data to compare our CAF clusters to
the well-defined myCAF, iCAF, apCAF clusters established by Elyada et al, 2019 (Figure
13A-B)81. We
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(A) UMAP projection of cell populations in KPC CAFs. aCAF: red, bCAF: yellow,
cCAF: green, dCAF: teal, eCAF: blue, fCAF: magenta. (B) UMAP projections of
iCAF (red), myCAF (green), and apCAF (blue) populations defined by Elyada et
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which correlated
to the myCAF
cluster (Figure
13C). Next, we
used our KTC

models to evaluate whether the transcriptional characterization of aSMA+ and FAP+ CAFs
led to functional outcomes in the TME. We performed microarray analysis on KTC; FAPtk
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and KTC; aSMAtk mice to assess changes in the TME when aSMA+ and FAP+ CAFs were
depleted. The pathways down regulated or upregulated when aSMA+ or FAP+ CAFs were
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Figure 14. αSMA+ and FAP+ CAFs distinctly polarize the PDAC tumor
immune microenvironment
(A-B) Differentially regulated pathways in endpoint αSMA and FAP-depleted
KTC tumors. (A) Microarray assessment of overlap in downregulated (top
panel) or upregulated (bottom panel) pathways in αSMA or FAP-depleted
KTC tumors. n=3 mice each group. (B) GSEA pathways identified after
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multiplex
immunohistochemistry
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to assess changes is the immune landscape of KTC; aSMAtk and KTC; FAPtk mice. We
found a significant decrease in the CD3+CD4+FoxP3-/ CD3+CD4+FoxP3+ ratio in KTC;
aSMAtk mice. When FAP+ CAFs were depleted there was a significant decrease in myeloid
cells and increase when aSMA+ CAFs were depleted (Figure 14C).

Interpretation of Findings
We established that aSMA+ and FAP+ CAFs have unique transcriptional profiles that lead to
distinct functions in PDAC immunity. Although our CAF subsets shared a cluster when we
assessed them by transcript, when we isolated aSMA+ and FAP+ CAFs via protein using
FACS, we confirmed that aSMA+ and FAP+ CAFs expressed unique transcripts. The
increase in immunosuppression in aSMA+ CAFs and the decrease in myeloid cells when
FAP+ CAFs are depleted from PDAC support our findings that aSMA+ CAFs are tumor
suppressing and FAP+ CAFs are tumor promoting.

Potential Pitfalls and Alternative Approaches
We establish that there are changes in the immune infiltrate when aSMA+ or FAP+ CAFs are
depleted. However, we do not know if the changes in the TME are directly due to the
depletion of our specific CAF subsets or if the CAFs were affecting another cell type that
was responsible for shaping PDAC immunity. We should broaden our focus on the cell
subsets affected by depletion of aSMA+ and FAP+ CAFs using imaging mass cytometry to
assess whether there were any non-immune cell types affected by aSMA+ and FAP+ CAF
depletion.

Future Directions
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The mechanism associated with the effects of aSMA+ and FAP+ CAFs on the immune
microenvironment in our model have yet to be uncovered. However, groups have suggested
a role of the SMAD/TGFB axis in myofibroblast CAFs influence on the immune
microenvironment and IL1/STAT3 axis as responsible for the functions of inflammatory CAF
subsets88,91. Therefore, we will next cross aSMA-Cre mice to LSL-TGFBRII mice and FAPCre mice to LSL-STAT3 mice to specifically knock out TGFBRII and STAT3 in aSMA+ and
FAP+ CAFs, respectively. We would then implant these mice orthotopically with our KPC line
and assess changes in the immune microenvironment compared to controls. This study will
help us establish the mechanism by which aSMA+ and FAP+ CAFs influence the immune
infiltrate in PDAC.
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Chapter 6

Discussion
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Discussion
Fibroblasts are a complex and dynamic cell type important in normal physiology, wound
healing, fibrosis, cancer, and a plethora of other disease states. However, the origins and
functions of fibroblast subsets continues to elude the field. The lack of specific fibroblast
markers likely contributes to our inability to fully define a fibroblast. However, as techniques
such as scRNAseq and mass cytometry become more widely available, we have seen great
advances in the TME field. Different CAF subsets have been characterized using
metabolomics, transcriptomics, proteomics, GEMMs, transgenic mice, and several other
tools to elucidate the currently known roles that CAFs play in the TME. Often, subsets of
fibroblasts are placed in two general pools, tumor promoting or tumor restraining. However,
as we evaluate these subsets we recognize that many CAF populations have characteristics
that both hinder and augment tumorigenesis. aSMA+ and FAP+ CAFs are two of the most
well studied subsets in PDAC. After the failure of several general stromal targeting
strategies in the clinic, groups began to assess the functional heterogeneity of CAFs in
PDAC. When two independent studies found that aSMA+ CAFs were anti-tumorigenic and
important in the maintenance of immune privilege in PDAC GEMMs, we began to
understand that unraveling the heterogeneity of CAFs may present new therapeutic options
in PDAC50,84. To this end CAR-T, small molecule inhibitors, and antibodies were developed
against FAP+ CAFs. FAP+ CAFs are known to be immune modulatory, pro-tumorigenic, and
pro-metastatic. Although, it could be hypothesized that aSMA+ and FAP+ CAFs had
differential roles in the TME, studies finding that aSMA+ and FAP+ CAFs are the same
population, aSMA+ CAFs are pro-tumorigenic, and that aSMA+ and FAP+ CAFs correlated to
decreased survival in patient cohorts have convoluted the assessment of aSMA+ and FAP+
CAFs in PDAC56,79,88,92,93. The difference in models, processing, and evaluation techniques
between studies likely contributes to the contradictory results.
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We began our study by assessing the stromal composition in two GEMMs. When we
discovered that aSMA+ and FAP+ CAFs were distinct cells by transcript and protein analysis,
we used GEMMs to assess aSMA+ and FAP+ CAFs in vivo. While, depletion of aSMA+
CAFs led to shortened survival in mice, poorly differentiated tumors, and immune
suppression; depletion of FAP+ CAFs led to increased murine survival, more normal
pancreas upon histological analysis, and a decrease in myeloid cells in the TME. In order to
establish the mechanism of aSMA+ and FAP+ CAFs manipulation of the immune
microenvironment we explored our scRNAseq data. Our expectation was that the
sequencing data would reveal the mechanisms involved in the shifts of the T-cell and
myeloid populations when aSMA+ and FAP+ CAFs were depleted from the TME. We
uncovered that aSMA+ CAFs express IL15, CD40, ICOS-L, CCL5, and CCL21 transcripts.
IL15 induces T-cell proliferation in non-regulatory T-cell subsets35. CD40 is an activation
receptor for antigen presenting cells94. ICOS-L is an important costimulatory molecule that
binds to ICOS on T-cells95. Most importantly, aSMA+ CAFs express both CCL5 and CCL21
which are potent T-cell chemoattractants96–99. The immune transcripts associated with
aSMA+ CAFs support our findings that when aSMA+ CAFs are depleted from the TME there
is a decrease in the CD4+FoxP3-/CD4+FoxP3+ ratio. It is reasonable to conclude that
expression of transcripts that are more commonly affiliated with the chemotaxis and
proliferation of non T-reg T-cell subsets by aSMA+ CAFs is the reason for the shift in the
Teff/Treg ratio when aSMA+ CAFs are depleted. However, we still need to perform
mechanistic studies to confirm our findings.
Unfortunately, our scRNAseq and microarray analysis data provided no further
insight into the mechanism involved in the increase or decrease in the presence of CD11b+
cells when aSMA+ CAFs or FAP+ CAFs are depleted, respectively. It may be useful to
isolate aSMA+ and FAP+ CAFs from KTC and KPC mice and perform cytokine arrays to
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identify potential mechanisms that could explain the ability for aSMA+ CAFs to repel myeloid
cells and FAP+ CAFs to attract myeloid cells. Along with understanding the potential
mechanisms involved in CAF shaping of the myeloid cell populations, it will be important to
follow up the work presented here within to understand the composition of the myeloid
population when aSMA+ and FAP+ CAFs are depleted from the TME. It is well known that in
the normal pancreas there are few MDSCs, particularly granulocytic MDSCS (GR-MDSCs).
But in PDAC this population expands and plays a crucial role in establishing the
immunosuppressive TME associated with PDAC. One could speculate that if FAP+ CAFs
were expressing GM-CSF or other factors important for MDSC maintenance, it could explain
the decrease in CD11b+ cells when FAP+ CAFs are depleted. Although there are still many
questions that have yet to be answered as to the true nature of the crosstalk between
aSMA+ and FAP+ CAFs and immune cells, we know that targeting the FAP+ CAF population
does result in a more favorable immune microenvironment in PDAC.
Discovering the functional contributions of aSMA+ and FAP+ CAFs in PDAC will allow
us to discriminately target FAP+ CAFs while sparing aSMA+ CAFs to shift the TME towards
a more anti-tumorigenic microenvironment. With the promise of new affective therapies on
the horizon as antibodies, cellular therapies, and small molecule inhibitors are developed to
target specific CAF populations, deconvolution of functional CAF heterogeneity has become
of the utmost importance. Predicting which CAF targets may synergize with specific
immunotherapies and standard of care treatments will allow us to develop clinical regimens
for PDAC and perhaps offer the first curative options to date.

Future Directions
Although our studies comprehensively analyzed two of the most common CAF subsets in
PDAC, several subsets have yet to be assessed that may prove to be much more beneficial
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targets in PDAC. Furthermore, since we only investigated models of PDAC, we currently do
not know if aSMA+ and FAP+ CAFs perform the same roles in the context of other cancers
with large stromal components such as breast cancer or colorectal cancer. In the future we
will expand our functional studies to include breast cancer and investigate other common
CAFs such as FSP1+ and vimentin+ CAF subsets.

Conclusion
In conclusion, we discovered that aSMA+ and FAP+ CAFs are two distinct subsets in PDAC
with opposing roles in tumor progression and differential effects on tumor immunity whose
functions in sum totality can be defined as tumor suppressing and tumor promoting,
respectively.
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